JWCA advises Oyster Point Pharma on its $125 million pre-approval debt and royalty financing

August 2021 | Press release

Transaction Background

Oyster Point Pharma, Inc. (“the Company”) hired J. Wood Capital Advisors as its Financial Advisor to advise on a pre-approval capital raise ahead of launching its first product, a novel nasal spray for dry eye disease

Objectives:

• Raise non-dilutive capital to fund the launch and commercialization of OC-01 nasal spray ahead of FDA approval

• Maintain upside in future OC-01 sales

• Receive near-term pre-approval proceeds to support the ramp up to launch

• Achieve competitive cost of capital

• Maintain operational and strategic flexibility

JWCA designed and ran a competitive process that could best help Oyster Point achieve its objectives. Upon obtaining terms from investors, JWCA:

• Analyzed various offers to help the Company select the proposal that best met its objectives

• Negotiated on Company’s behalf to improve transaction structure

Results

Helped the Company to raise significant non-dilutive capital at a key pre-approval stage

Achieved financing outcome that balanced the Company’s objectives, including maximizing near-term proceeds at a competitive cost of capital